Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017402 | 0.87 | APP (0.49) | APPKMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL12987482 | 0.80 | MEN1 (0.35) | APPKMT2AMEN1MAPT | |
| SCHEMBL3338194 | 0.74 | APP (0.40) | APPKMT2AMEN1CYP1A2MAPT | |
| SCHEMBL12017485 | 0.74 | MCL1 (0.52) | — | |
| SCHEMBL2021856 | 0.74 | AURKA (0.36) | APPKMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL20137819 | 0.70 | SRC (0.48) | KMT2A | |
| SCHEMBL12015680 | 0.70 | APP (0.46) | APP | |
| SCHEMBL12017477 | 0.69 | AR (0.46) | KMT2AMEN1MAPT | |
| SCHEMBL12987122 | 0.69 | HTT (0.35) | MAPT | |
| SCHEMBL1233635 | 0.68 | SLC22A12 (0.45) | KMT2AMEN1CYP1A2CYP3A4SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | APP 128/4885KMT2A 2708/4885MEN1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.